-
HavRx Insights: Watch List Check-Up
You need to be logged in to view this content. Please Log In. Not a Member?…
-
enVVeno Medical (NVNO): Overview and Outlook
You need to be logged in to view this content. Please Log In. Not a Member?…
-
HavRx Insights: Watch List Updates
You need to be logged in to view this content. Please Log In. Not a Member?…
-
Nuvation Bio (NUVB): Overview and Outlook
You need to be logged in to view this content. Please Log In. Not a Member?…
-
Silo Pharma (SILO): Overview and Outlook
You need to be logged in to view this content. Please Log In. Not a Member?…
-
Hoth Thera (HOTH) Surges on Preclinical Obesity Data
You need to be logged in to view this content. Please Log In. Not a Member?…
-
HavRx Insights Trade Alert
You need to be logged in to view this content. Please Log In. Not a Member?…
-
Skye Bio (SKYE): Big Potential in Weight Loss
You need to be logged in to view this content. Please Log In. Not a Member?…
-
Black Diamond Thera (BDTX) Overview and Outlook
You need to be logged in to view this content. Please Log In. Not a Member?…
-
ImmuCell (ICCC) Overview and Outlook
You need to be logged in to view this content. Please Log In. Not a Member?…
Watch List News Flow
- Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates
- Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
- High Growth Tech Stocks In Europe For March 2025
- Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts
- Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Black Diamond: Q4 Earnings Snapshot
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
- VALNEVA Declaration of shares and voting rights: February 28, 2025
- Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
- Immuneering Slides As Insider Purchases Lose Another US$186k
- Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
- Nuvation Bio secures $250m for taletrectinib commercialisation
- Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
- Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
- PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
- Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
- ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
- US High Growth Tech Stocks With Strong Potential
- Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Clinical Trial News Flow
- ViiV Healthcare’s Investigational Broadly Neutralising Antibody – N6LS – Successfully Maintains Viral Suppression in Long-Acting Treatment of HIV
- Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
- Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
- First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
- Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
- CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in the REDEFINE 2 Trial
- Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients
- Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata
- Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis
- Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis
- PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
- Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
- Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
- Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Cost of All Doses of FDA-Approved Wegovy® (semaglutide) to $499 per Month
- NIH-Funded Research Team Engineers New Drug Targeting Pain Sensation Pathway
- Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301
- Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Webull Free Shares Offer
Webull is my preferred online broker since 2023. In my 20+ years of trading, I have used all of the well-known online brokers and none can match the combination of user-friendly yet feature-rich services that Webull provides with its commission-free service. I use the desktop trading application and mobile app which continue to improve and add new features. My favorite features are the customizable streaming watch list and charting tools. Finally, Webull has great customer service, quick/free cash transfers and I highly recommend it for investors of all experience levels.